Navigation Links
Jade Therapeutics Elects Veteran Life Science Entrepreneur Dinesh Patel, Ph.D., to its Board of Directors
Date:11/13/2013

SALT LAKE CITY, Nov. 13, 2013 /PRNewswire/ -- Jade Therapeutics, Inc. announced today the election of veteran life science entrepreneur and venture capitalist Dinesh Patel, Ph.D., to the Company's Board of Directors, replacing SCI Institute Associate Director Dr. Greg Jones.

(Logo: http://photos.prnewswire.com/prnh/20131113/PH15704LOGO

Dr. Patel co-founded the venture capital firm vSpring Capital (now Signal Peak Ventures) in 2000 and is currently Partner Emeritus. From 1985-1999, he served as Co-Founder, Chairman, and President & CEO of TheraTech, Inc., a biotechnology company that he took public and eventually sold to Watson Pharmaceuticals for $350 million. He was also Founder, Chairman, President & CEO of Ashni Naturaceuticals, and he co-founded and was Chairman of the biotechnology company Salus Therapeutics. In addition, he served on the Board of online medical records provider MediConnect Global, Inc., which was acquired in 2012 by Verisk Analytics for $350 million.

Dr. Patel is currently Chairman of USTAR's Governing Authority board and has won numerous awards including the 2006 Utah Technology Council Hall of Fame Inductee, the U.S. Small Business Administration's Business Achiever Award, Entrepreneur of the Year (Mountain West Venture Group), and most recently BioUtah's flagship award, the Willem J. Kolff Lifetime Achievement Award.

"We are grateful to Greg for his important assistance to Jade from our company's earliest days, and we are indeed honored that Dinesh is now joining our Board," said Jade CEO Arthur Klausner.  "Dinesh's wealth of experience in both drug delivery and ophthalmology represents a terrific fit for Jade as we continue to progress our locally administered, sustained-release drug products designed to treat significant ocular disorders such as corneal defects and ulcers. He is well known and respected both in the Salt Lake City area and nationally for his entrepreneurial and company-building achievements, and he has served on the Boards of numerous start-up life sciences companies."

Said Dr. Patel: "Jade represents an attractive combination of proprietary, lower-risk products addressing unmet needs in potentially blinding ophthalmic conditions. I look forward to working with the Company's Board and management team to help bring these products to the patients who need them."

About Jade Therapeutics

Jade Therapeutics, founded by Drs. Barbara Wirostko and MaryJane Rafii, is a privately held company headquartered in Salt Lake City, Utah, that develops locally administered, sustained-release formulations of (mostly) already-approved drugs for use in poorly served ophthalmic indications. This approach could enable improved therapeutic outcomes along with increased patient compliance to therapy, decreased frequency of administration and office visits, and avoidance of subsequent surgeries – ultimately resulting in better visual function with enhanced quality of life.  Jade believes that its use of proprietary administration formulations of drugs that have already received regulatory approval may significantly decrease development risks and shorten the clinical trial and regulatory approval process. Jade's lead programs focus on delivering (1) recombinant human growth hormone to help address persistent corneal epithelial defects, and (2) antibiotics to treat bacterial keratitis and corneal ulcers (utilizing funding from a recently awarded National Science Foundation SBIR grant). For additional information about Jade, please visit www.jadetherapeutics.com

Contact:
Arthur Klausner
Jade Therapeutics, Inc.
646-918-7479
Email

 

Read more news from Jade Therapeutics.

 


'/>"/>
SOURCE Jade Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
2. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
3. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
4. Convoy Therapeutics Appoints Clinical Advisory Board
5. Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
6. United Therapeutics Corporation Reports Third Quarter 2013 Financial Results
7. The Zacks Analyst Blog Highlights: Eaton, Baxter International, Bio-Rad Laboratories, INSYS Therapeutics and Boston Scientific
8. Moderna Therapeutics Named to the World Economic Forums Community of "Global Growth Companies"
9. United Therapeutics Corporation to Announce Third Quarter 2013 Financial Results Before Market Open on Tuesday, October 29, 2013
10. PTC Therapeutics Expands Management Team
11. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... AR (PRWEB) , ... July 20, 2017 , ... ... Rogers is joining the company’s board of directors. This addition continues to strengthen ... board," said Calvin Goforth, CEO and Chairman. “He is a highly accomplished business executive ...
(Date:7/18/2017)... ... July 18, 2017 , ... Nanomedical ... biotherapeutics development, announces the launch of a new NTA biosensor chip for use ... to study the kinetics of polyhistidine-tagged (His-tagged) molecules quickly and reliably. , ...
(Date:7/18/2017)... ... 18, 2017 , ... Allotrope Foundation won the 2017 in ... the Allotrope Framework for commercial use. , The Bio-IT World Best Practices Awards ... the critical role of information technology in modern biomedical research, but also to ...
(Date:7/17/2017)... ... July 17, 2017 , ... ... instruments announced the launch of its new line of Heavy-Duty Orbital Shakers today. ... (both analog and digital) for laboratory applications. These shakers are ideal for ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
Breaking Biology News(10 mins):